Hirulog-like peptide and gene therapy

Abstract

There is provided a hirulog-like peptide. Also provided is the treatment of vascular restenosis including the steps of administering an effective amount of a hirulog-like peptide in a pharmaceutically acceptable carrier whereby administration prevents vascular restenosis. A pharmaceutical composition including a hirulog-like peptide and a pharmaceutically acceptable carrier is also provided. A vector expressing a hirulog-like peptide is also provided. Also provided by the present invention is a method of treating a patient with vascular restenosis by introducing to the patient an amount of a sequence encoding a hirulog-like peptide sufficient to prevent vascular restenosis.

1. A hirulog-like peptide comprising amino acids 1-32 of SEQ ID No. 1. 
     
     
       2. A method for treatment of vascular restenosis by reducing injury-induced neointima formation in an atherosclerotic mammal which method comprises providing a patient in need of treatment for restenosis an intravenous administration of an effective amount of a hirulog-like peptide (HLP) comprising amino acids 1-32 of SEQ ID No. 1. 
     
     
       3. A pharmaceutical composition comprising a hirulog-like peptide comprising amino acids 1-32 of SEQ ID No. 1 and a pharmaceutically acceptable carrier.